Skip to main content

InforSense, Ingenuity Systems, NIH, BioSolution, Clarient, Cornell University

Premium
InforSense and Ingenuity Systems Integrate KDE and IPA
 
InforSense said this week that Ingenuity Systems has joined the InforSense Open Workflow Partner Network and that the companies have partnered to integrate InforSense KDE and Ingenuity Pathway Analysis.
 
This collaboration will allow customers of both firms to build workflows with newly available IPA nodes that are now available through InforSense.
 
Customers will be able to use the IPA nodes as part of their KDE analysis workflows to allow data to be uploaded and analyzed automatically. Users can also view gene and gene neighbor information generated from a KDE workflow.
 

 
NIH to Award $1.5M in FY‘07 for ENCODE DataCoordinationCenter
 
The National Human Genome Research Institute plans to award $1.5 million in fiscal year 2007 for a data-coordination center to support the Encyclopedia of DNA Elements project.
 
In a request for applications issued last week, NHGRI said the DCC “will be funded primarily to develop, house, and maintain databases to track, store, and provide access to different types of data generated as part of the ENCODE Project. In addition, the DCC will import data from related projects that are relevant to the goals of the ENCODE Project.”
 
Further information about the DCC RFA is available here.
 
The ENCODE project is currently in a pilot phase focused on developing methods for identifying functional elements in genomic DNA in 1 percent of the human genome. Last week, NHGRI issued a companion RFA, “Creating the Encyclopedia of DNA Elements (ENCODE) in the Human Genome,” to continue the support of pilot projects and to support production centers that will expand the ENCODE Project to the entire genome.
 
Under that RFA, available here, NHGRI will award between six and 10 awards for a total of $23 million in FY 2007.
 
NHGRI expects to grant one DCC award with a project period of up to four years. Letters of intent are due Feb. 27, 2007, while applications are due March 29, 2007.
 

 
BioSolution to Distribute Integromics Software in France
 
Madrid-based bioinformatics firm Integromics said this week that BioSolution of Evry, France, will resell its software in France.
 
Integromics provides software for data management, data integration, and data mining for genomics and proteomics, while BioSolution offers professional consulting, project management, and integration services for life sciences research companies, biotechs, and academic labs.
 

 
Clarient to Use Natural Selection’s Algorithms for Cancer Biomarker Discovery
 
Pathology services firm Clarient said this week that it has gained an exclusive, worldwide, non-transferable license to apply algorithms developed by Natural Selection to discover oncology biomarkers.
 
The companies signed a three-year agreement to develop in vitro diagnostics for cancer detection.
 
Natural Selection’s algorithms “will aid in the development of clinically relevant biomarkers either in-house or through collaborations with biotech firms as well as academic medical centers,” said Ron Andrews, Clarient’s president and CEO.
 
“We expect the resulting novel markers to produce incremental recurring revenues generated by Clarient directly through its laboratory services group as well as through licensing agreements with third parties,” he added. 
 
Clarient will offer its biomarker discovery services to biotechnology companies for the development and commercialization of novel cancer markers for diagnosis, prognosis, and therapy selection.
 
Financial terms of the agreement were not provided.
 

 
Cornell Licenses DNAStar's Lasergene Sequencing Software
 
DNAStar said this week that it has licensed its Lasergene sequence analysis software to Cornell University.
 
Financial terms of the agreement were not released.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.